What is the current Price Target for the Iterum Therapeutics Plc stock?

The average Iterum Therapeutics Plc target price is $10.00. This is 631.53% higher than the current stock price. 1 Analyst has issued a Iterum Therapeutics Plc price target 2026.

How high will the Iterum Therapeutics Plc stock rise?

No reliable answer can be given as to how high the Iterum Therapeutics Plc stock will rise. The performance of stocks, including the Iterum Therapeutics Plc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Iterum Therapeutics Plc stock today?

The performance of Iterum Therapeutics Plc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Iterum Therapeutics Plc stock fall?

The decline in Iterum Therapeutics Plc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Iterum Therapeutics Plc Forecast, price target & analysts

$1.38

1.52% yesterday

Nasdaq, Feb 28, 08:45 pm CET

ISIN

IE00BF3W0Q35

Symbol

ITRM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Iterum Therapeutics Plc Target price 2025 - Analyst rating & recommendation

Iterum Therapeutics Plc Classifications & Recommendation:

Buy

100%

Iterum Therapeutics Plc Price Target

Target Price	$10.00
Price	$1.37
Potential	631.53% register free of charge
Number of Estimates	1

	1 Analyst has issued a Iterum Therapeutics Plc price target 2026. The average Iterum Therapeutics Plc target price is $10.00. This is 631.53% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Iterum Therapeutics Plc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Iterum Therapeutics Plc stock has an average upside potential 2026 of 631.53% register free of charge . Most analysts recommend the Iterum Therapeutics Plc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.26	-0.64
	57.43%	49.21%
P/E		negative
EV/Sales		6.26

1 Analysts have issued a Iterum Therapeutics Plc forecast for earnings per share. The average Iterum Therapeutics Plc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.26	57.43%
2025	$-0.64 49.21% Unlock
2026	$-0.51 20.31% Unlock
2027	$0.07 113.73% Unlock
2028	$1.76 2,414.29% Unlock
2029	$3.63 106.25% Unlock

Current	-1.04	100.00%
2025	-2.33 124.04% Unlock
2026	-2.92 25.32% Unlock
2027	21.29 829.11% Unlock
2028	0.85 96.01% Unlock
2029	0.41 51.76% Unlock

Iterum Therapeutics Plc...

Current Iterum Therapeutics Plc Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 10 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 10 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now